Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors

Biochemical Pharmacology

Volumn 57, Issue 12, 1999, Pages 1375-1382

  Allen, Rodger A ^a   Merriman, Mark W ^a   Perry, Martin J ^a   Owens, Raymond J ^a  

^a UCB PHARMA   (Belgium)

Author keywords

cAMP; CHO cells; PDE4 inhibitors; PDE4 isoforms; Phosphodiesterase type 4; Sc Sr binding sites

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; BETA ADRENERGIC RECEPTOR; CILOMILAST; CYCLIC AMP; ISOENZYME; ISOPRENALINE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROLIPRAM; RS 25344; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL TYPE; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENETIC TRANSFECTION; GUINEA PIG; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENERGIC BETA-AGONISTS; ANIMALS; CATALYSIS; CHO CELLS; COS CELLS; CRICETINAE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; ISOENZYMES; ISOPROTERENOL; RECEPTORS, ADRENERGIC, BETA-2; RECOMBINANT PROTEINS; TIME FACTORS; TRANSFECTION;

EID: 0032931616     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00062-3     Document Type: Article

References (33)

1. Beavo J.A., Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci. 11:1990;150-155.
2. Thompson W.J. Cyclic nucleotide phosphodiesterases Pharmacology, biochemistry and function . Pharmacol Ther. 51:1991;13-33.
3. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., Cheng J.B. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Comm. 246:1998;570-577.
4. Soderling S.H., Bayuga S.J., Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem. 273:1998;15553-15558.
5. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., Cheng J.B. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 273:1998;15559-15564.
6. Torphy T.J., Undem B.J. Phosphodiesterase inhibitors New opportunities for the treatment of asthma . Thorax. 46:1991;512-523.
7. Giembycz M.A. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol. 43:1992;2041-2051.
8. Sekut L., Yarnall D., Stimpson S.A., Noel L.S., Bateman-Fite R., Clark R.L., Brackeen M.F., Menius L.A., Connolly K.M. Anti-inflammatory activity of phosphodiesterase (PDE) IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol. 100:1995;126-132.
9. Genain C.P., Roberts T., Davis R.L., Nguyen M.-H., Uccelli A., Faulds D., Li Y., Hedgpeth J., Hauser S.L. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA. 92:1995;3601-3605.
10. Sommer N., Loschmann P.-A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., Dichgans J., Martin R. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med. 1:1995;244-248.
11. Giembycz M.A., Dent G. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin Exp Allergy. 22:1992;337-344.
12. Bolger G., Rodgers L., Riggs M. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene. 149:1994;237-244.
13. Huston E., Pooley L., Julien P., Scotland G., McPhee I., Sullivan M., Bolger G., Houslay M.D. The human cyclic AMP-specific phosphodiesterase PDE46 (HSPDE4A4B) expressed in transfected COS 7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem. 271:1996;31334-31344.
14. O'Connell J.C., McCallum J.F., McPhee I., Wakefield J., Houslay E.S., Wishart W., Bolger G., Frames M., Houslay M.D. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE45). Biochem J. 318:1996;255-262.
15. Torphy T.J., Stadel J.M., Burman M., Cieslinski C.B., McLaughlin M.M., White J.R., Livi J.R. Coexpression of human cAMP-specific phosphodiesterase activity and high-affinity rolipram binding yeast. J Biol Chem. 267:1992;1798-1804.
16. m, rolipram-sensitive cAMP-specific phosphodiesterase from human brain. J Biol Chem. 268:1993;6470-6476.
17. Hughes B., Owens R., Perry M., Warrellow G., Allen R. PDE4 inhibitors The use of molecular cloning in the design and development of novel drugs . Drug Disc Today. 2:1997;89-101.
18. Barnette M.S., Grous M., Cieslinski L.B., Burman M., Christensen S.B., Torphy T.J. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands Correlation between function and interaction with a high-affinity rolipram binding site . J Pharmacol Exp Ther. 273:1995;1396-1402.
19. Owens R.J., Catterall C., Batty D., Jappy J., Russell A., Smith B.J., O'Connell J., Perry M.J. Human phosphodiesterase 4A Characterization of full-length and truncated enzymes expressed in COS cells . Biochem J. 326:1997;53-60.
20. Bolger G., Michaeli T., Martins T., St John T., Steiner B., Rodgers L., Riggs M., Ferguson K. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for anti-depressant drugs. Mol Cell Biol. 13:1993;6558-6571.
21. Owens R.J., Lumb S., Rees-Milton K., Russell A., Baldock D., Lang V., Crabbe T., Ballesteros M., Perry M.J. Molecular cloning and expression of a human phosphoidesterase 4C. Cell Signal. 9:1997;575-585.
22. Nemoz G., Zhang R.B., Sette C., Conti M. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett. 384:1996;97-102.
23. Cockett M.I., Bebbington C.R., Yarranton G. The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines. Nucleic Acids Res. 19:1991;319-325.
24. Perry M., O'Connell J., Walker C., Crabbe T., Baldock D., Russell A., Lumb S., Huang Z., Howat D., Allen R., Merriman M., Walls J., Daniel T., Hughes B., Laliberte F., Higgs G.A., Owens R.J. CDP840, a novel inhibitor of phosphodiesterase type 4. Cell Biochem Biophys. 29:1998;113-132.
25. Schneider H.H., Schmiechen R., Brezinski M., Seidler J. Stereospecific binding of the anti-depressant rolipram to brain protein structures. Eur J Pharmacol. 127:1986;105-115.
26. 1B) and calcitonin (C1a) receptors in CHO cells to a cyclic AMP-responsive luciferase reporter gene. J Neurochem. 69:1997;1278-1285.
27. Alvarez R., Sette C., Yang D., Eglen R., Wilhelm R., Shelton E.R., Conti M. Activation and selective inhibition of a cyclic AMP phosphodiesterase, PDE-4D3. Mol Pharmacol. 48:1995;616-622.
28. Sette C., Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase Involvement of serine 54 in the enzyme activation . J Biol Chem. 271:1996;16526-16534.
29. Conti M., Nemoz G., Sette C., Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev. 16:1995;370-389.
30. Sette C., Iona S., Conti M. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem. 269:1994;9245-9252.
31. Sette C., Vicini E., Conti M. The rat PDE 3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J Biol Chem. 269:1994;18271-18274.
32. 3H] rolipram binding activity and their relationship to emetic behaviour in the ferret . J Med Chem. 39:1996;120-125.
33. Saccomano N.A., Vinick F.J., Koe K., Nielsen J.A., Whalen W.M., Meltz M., Phillips D., Thadieo P.F., Jung S., Chapin D.S., Lebel L.A., Russo L.L., Helwig D.A., Johnson J.L. Jr, Ives J.L., Williams I.H. Calcium-independent phosphodiesterase inhibitors as putative antidepressants [3-(bicycloalkoxy)-4-methoxy-phenyl]-2-imidazo-lidinones . J Med Chem. 34:1991;291-298.